SAN DIEGO, Dec. 3, 2016 /PRNewswire/ -- Dr. Andre Goy, Cota board member and President of the John Theurer Cancer Center, will present a new study utilizing real-world evidence to demonstrate the importance of comorbidities on outcomes of patients with mantle cell lymphoma at the 58th American Society of Hematology Annual Meeting & Exposition in San Diego, taking place December 3-6.

Poster Presentation Information:

About Cota:
Cota is a technology platform that enables providers, payers, and life science companies involved in diagnosing and treating complex diseases to optimize the care of individual patients and lower the overall cost of the patient population served. It is powered by the patented Cota Nodal Address™ (CNA) system, a unique digital classification methodology built by leading physicians and data scientists. The CNA is the first and only system that precisely categorizes patient factors, their diseases and intended therapies, enabling precision medicine at scale.

Cota's technology enriches raw medical records to create research-grade data, and joins it with a suite of analysis, visualization, and management tools. This enables providers, payers, and life sciences companies to analyze, report on, and research outcomes, costs, treatments, and quality at any granularity and stage of the patient journey. The result is a constantly improving system that merges technology and science to help improve the lives of patients everywhere.

Matthew Levin
Email: press@oncota.com  
Phone: +1 (646) 543-2682

Logo - http://photos.prnewswire.com/prnh/20161129/443604LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-andre-goy-and-cota-will-present-impact-of-charlson-comorbidity-index-cci-and-refining-the-mipi-index-in-mantle-cell-lymphoma-at-58th-american-society-of-hematology-annual-meeting--exposition-300372511.html

SOURCE Cota